Fight, Flight, or Stoned: targeting the adrenergic system in cannabis use disorder
Friday, August 23, 2024
12:30PM - 2:00PM PDT
This seminar will review identification of cannabis use disorder (CUD), clinical aspects of cannabis withdrawal symptoms, and medications which have been tested for CUD. Particular attention will be made to the interconnections of cannabis use and the adrenergic system.
Location: Online
Continuing Education: 1.5 (Applied through NASW Oregon)
Cost: Free to RVP Volunteers, Vet Center and VA Staff and Partnering Clinics
$29 for Other Community Providers
Who Should Attend: This training is open to all RVP Volunteer Providers, social workers, mental health counselors, and community providers.
What You Will Learn:
Rates of cannabis use disorder are increasing in Veterans, yet no medications are available for its treatment. Given increased access and perception of decreased risk, recognition of cannabis use disorder can be difficult for individuals. Furthermore, identification of cannabis withdrawal symptoms have high overlap with neuropsychiatric disorder symptoms, creating a challenge in their attribution to cannabis use.
Despite extensive study, no medications for cannabis use disorder are yet available. Here we will review medications studied to date, with particular attention to those that interact with the noradrenergic system.
Learning Objectives
At the end of this presentation, the learner will be able to:
- Recognize the symptoms and clinical presentation of cannabis use disorder
- Describe cannabis withdrawal symptoms and their potential overlap with comorbid clinical disorders
- LExamine how reducing noradrenergic tone has potential for treatment of cannabis use disorder and/or cannabis withdrawal.
CE Faculty
Garth Terry, MD, PhD is an Assistant Professor in the UW School of Medicine Departments of Psychiatry and Behavioral Sciences and Radiology and a Physician/Research Career Development Award Associate in the Mental Illness Research, Education, and Clinical Center (MIRECC) at the VA Puget Sound in Seattle. His Ph.D. was completed at the National Institute of Mental Health and Karolinska Institute in Stockholm, Sweden with the dissertation, “In vivo imaging of the cannabinoid CB1 receptor using positron emission tomography.” He received his medical degree from George Washington University in Washington, DC, and trained in psychiatry at UCLA. He is principal investigator of, “Pilot study to assess the feasibility of prazosin for cannabis use disorder in individuals with or without posttraumatic stress disorder.” He has over a dozen peer reviewed publications and presents frequently on the pharmacology and clinical impact of cannabis.
Want to attend our trainings for free? Become an RVP Volunteer and gain access to free CE trainings and other great benefits! Learn more about volunteering >
Contact: Jennifer Keeling, RVP Health Network Volunteer and Engagement Manager .(JavaScript must be enabled to view this email address)
503-954-2259
Share this online:
